ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer
- PMID: 34493587
- PMCID: PMC11910188
- DOI: 10.1136/ijgc-2021-002921
ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer
Abstract
Objective: The objective of the ConCerv Trial was to prospectively evaluate the feasibility of conservative surgery in women with early-stage, low-risk cervical cancer.
Methods:
From April 2010 to March 2019, a prospective, single-arm, multicenter study evaluated conservative surgery in participants from 16 sites in nine countries. Eligibility criteria included: (1) FIGO 2009 stage IA2-IB1 cervical carcinoma; (2) squamous cell (any grade) or adenocarcinoma (grade 1 or 2 only) histology; (3) tumor size
Results: 100 evaluable patients were enrolled. Median age at surgery was 38 years (range 23-67). Stage was IA2 (33%) and IB1 (67%). Surgery included conization followed by lymph node assessment in 44 women, conization followed by simple hysterectomy with lymph node assessment in 40 women, and inadvertent simple hysterectomy followed by lymph node dissection in 16 women. Positive lymph nodes were noted in 5 patients (5%). Residual disease in the post-conization hysterectomy specimen was noted in 1/40 patients-that is, an immediate failure rate of 2.5%. Median follow-up was 36.3 months (range 0.0-68.3). Three patients developed recurrent disease within 2 years of surgery-that is, a cumulative incidence of 3.5% (95% CI 0.9% to 9.0%).
Discussion: Our prospective data show that select patients with early-stage, low-risk cervical carcinoma may be offered conservative surgery.
Keywords: cervix uteri; hysterectomy; lymph nodes; surgery.
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: The authors have the following disclosures: MH: consulting/speaker for Stryker and research support from GlaxoSmithKline and Astra Zeneca.
Figures

Comment in
-
ConCerv: a prospective trial of conservative surgery for low-risk early stage cervical cancer, by Schmeler et al.Int J Gynecol Cancer. 2021 Oct;31(10):1326-1327. doi: 10.1136/ijgc-2021-003008. Epub 2021 Sep 24. Int J Gynecol Cancer. 2021. PMID: 34561221 No abstract available.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
-
- Organization TWH. Global strategy to accelerate the elimination of cervical cancer as a public health problem, 2018. Available: https://www.who.int/publications/i/item/9789240014107
-
- Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974;44:265–72. - PubMed
-
- Plante M, Gregoire J, Renaud M-C, et al. The vaginal radical trachelectomy: an update of a series of 125 cases and 106 pregnancies. Gynecol Oncol 2011;121:290–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous